Insider Selling: Scholar Rock (NASDAQ:SRRK) Insider Sells $607,034.22 in Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) insider Akshay Vaishnaw sold 12,246 shares of the firm’s stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $49.57, for a total transaction of $607,034.22. Following the transaction, the insider owned 630,542 shares of the company’s stock, valued at approximately $31,255,966.94. This represents a 1.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Scholar Rock Stock Down 1.6%

Shares of SRRK opened at $47.33 on Thursday. The stock has a market cap of $5.44 billion, a price-to-earnings ratio of -13.80 and a beta of 0.68. The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.41. Scholar Rock Holding Corporation has a 12 month low of $27.07 and a 12 month high of $51.63. The company has a 50-day moving average price of $46.17 and a two-hundred day moving average price of $42.23.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.76) EPS for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.10. During the same quarter in the prior year, the firm posted ($0.64) EPS. Equities analysts predict that Scholar Rock Holding Corporation will post -3.13 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have commented on SRRK shares. Citigroup raised their price target on shares of Scholar Rock from $55.00 to $58.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Truist Financial raised their price objective on shares of Scholar Rock from $44.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. Wedbush raised their price objective on shares of Scholar Rock from $56.00 to $58.00 and gave the stock an “outperform” rating in a report on Wednesday, April 1st. BMO Capital Markets raised their price objective on shares of Scholar Rock from $50.00 to $70.00 and gave the stock an “outperform” rating in a report on Wednesday, March 4th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $58.00 price objective on shares of Scholar Rock in a report on Tuesday, March 3rd. Five research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $55.40.

Institutional Trading of Scholar Rock

Several hedge funds have recently modified their holdings of the company. Three Seasons Wealth LLC increased its holdings in shares of Scholar Rock by 2.1% during the fourth quarter. Three Seasons Wealth LLC now owns 10,968 shares of the company’s stock worth $483,000 after buying an additional 222 shares in the last quarter. Values First Advisors Inc. increased its holdings in shares of Scholar Rock by 1.5% during the first quarter. Values First Advisors Inc. now owns 18,850 shares of the company’s stock worth $927,000 after buying an additional 286 shares in the last quarter. IFP Advisors Inc increased its holdings in shares of Scholar Rock by 294.1% during the fourth quarter. IFP Advisors Inc now owns 603 shares of the company’s stock worth $27,000 after buying an additional 450 shares in the last quarter. Principal Financial Group Inc. increased its holdings in shares of Scholar Rock by 7.9% during the third quarter. Principal Financial Group Inc. now owns 6,214 shares of the company’s stock worth $231,000 after buying an additional 456 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its holdings in shares of Scholar Rock by 151.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock valued at $38,000 after purchasing an additional 525 shares in the last quarter. Institutional investors and hedge funds own 91.08% of the company’s stock.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).